Search Results - Nilla Avanzi

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515

    Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515 by Gianluca Papeo, Paolo Orsini, Nilla Avanzi, Daniela Borghi, Elena Casale, Marina Ciomei, Alessandra Cirla, Viviana Desperati, Daniele Donati, Eduard Felder, Arturo Galvani, Marco Guanci, Antonella Isacchi, Helena Posteri, Sonia Rainoldi, Federico Riccardi Sirtori, Alessandra Scolaro, Alessia Montagnoli

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy

    Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy by Clara Albanese, Rachele Alzani, Nadia Amboldi, Nilla Avanzi, Dario Ballinari, Maria Gabriella Brasca, Claudio Festuccia, Francesco Fiorentini, Giuseppe Locatelli, Wilma Pastori, Veronica Patton, Fulvia Roletto, Francesco Colotta, Arturo Galvani, Antonella Isacchi, Jürgen Moll, Enrico Pesenti, Ciro Mercurio, Marina Ciomei

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase

    Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase by Riccardo Colombo, Marina Caldarelli, Milena Mennecozzi, Maria Laura Giorgini, Francesco Sola, Paolo Cappella, Claudia Perrera, Stefania Re Depaolini, Luisa Rusconi, Ulisse Cucchi, Nilla Avanzi, J. A. Bertrand, R Bossi, Enrico Pesenti, Arturo Galvani, Antonella Isacchi, Francesco Colotta, Daniele Donati, Jürgen Moll

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Divergent effects of RIP1 or RIP3 blockade in murine models of acute liver injury

    Divergent effects of RIP1 or RIP3 blockade in murine models of acute liver injury by Melanie Deutsch, Christopher S. Graffeo, Rae S. Rokosh, Mridul Pansari, Atsuo Ochi, Elliot Levie, E Van Heerden, Daniel Tippens, Salvatore Greco, Rocky Barilla, Lena Tomkötter, Constantinos P. Zambirinis, Nilla Avanzi, Rishabh Gulati, H. Leon Pachter, Alejandro Torres-Hernandez, Andrew Eisenthal, Donnele Daley, George Miller

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies

    NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies by Barbara Valsasina, Italo Beria, Cristina Alli, Rachele Alzani, Nilla Avanzi, Dario Ballinari, Paolo Cappella, Michele Caruso, Alessia Casolaro, Antonella Ciavolella, Ulisse Cucchi, Anna De Ponti, Eduard Felder, Francesco Fiorentini, Arturo Galvani, Laura Gianellini, Maria Laura Giorgini, Antonella Isacchi, Jaqueline Lansen, Enrico Pesenti, Simona Rizzi, Maurizio Rocchetti, Francesco Sola, Jürgen Moll

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition

    The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition by Elena Ardini, Roberta Bosotti, Andrea Borgia, Cristina Ponti, Alessio Somaschini, Rosaria Cammarota, Nadia Amboldi, Laura Raddrizzani, Andrea Milani, Paola Magnaghi, Dario Ballinari, Daniele Casero, Fabio Gasparri, Patrizia Banfi, Nilla Avanzi, Maria Beatrice Saccardo, Rachele Alzani, Tiziano Bandiera, Eduard Felder, Daniele Donati, Enrico Pesenti, Andrea Sartore‐Bianchi, Marcello Gambacorta, Marco A. Pierotti, Salvatore Siena, Silvio Veronese, Arturo Galvani, Antonella Isacchi

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

    Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications by Elena Ardini, Maria Menichincheri, Patrizia Banfi, Roberta Bosotti, Cristina Ponti, Romana Pulci, Dario Ballinari, Marina Ciomei, Gemma Texidó, Anna Degrassi, Nilla Avanzi, Nadia Amboldi, Maria Beatrice Saccardo, Daniele Casero, Paolo Orsini, Tiziano Bandiera, Luca Mologni, David W. Anderson, Wei Ge, Jason Harris, Jean‐Michel Vernier, Gang Li, Eduard Felder, Daniele Donati, Antonella Isacchi, Enrico Pesenti, Paola Magnaghi, Arturo Galvani

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: